Overview

A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever

Status:
Not yet recruiting

Trial end date:
2024-11-07

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety, reactogenicity, and immune response induced by the GlaxoSmithKline Biologicals SA (GSK) Vaccines Institute for Global Health (GVGH) invasive nontyphoidal Salmonella-typhoid conjugate (iNTS-TCV) candidate vaccine to be administered for the first time in humans. The study intervention will be evaluated in European adults in Stage 1 (a 2-step staggered design) followed by African adults in Stage 2.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

GlaxoSmithKline

Collaborators:

Biomedical Advanced Research and Development Authority
Wellcome Trust

Treatments:

Vaccines